Molecular diagnostic platform comparison should begin with the testing workflow the organization must support, then work backward to instrument specifications. A CDC workgroup reviewing nucleic acid amplification platforms prioritized suitability for research, surveillance and diagnostic testing; compatibility with existing tests; 96-well or higher throughput; FDA clearance potential; software flexibility; and laboratory-developed test capability before considering size, consumables and cost [1]. Those criteria expose a recurring procurement tension: one platform may fit reference laboratory throughput while another supports distributed or near-patient testing. Buyers should therefore treat platform choice as a resource allocation decision across sample volume, test menu, staffing and service infrastructure rather than a specification-only exercise [3][5].
Start with required workflow and severity of use
A platform comparison is meaningful only when the intended operational role is defined. The PFSCM procurement guidance for HIV viral load and early infant diagnosis distinguishes centralized, high-throughput instruments from near-point-of-care, lower-throughput automated systems, noting that many platforms are polyvalent across HIV, EID, SARS-CoV-2, tuberculosis, hepatitis C and HPV depending on the supplier menu [3]. Procurement teams should first document whether the instrument will process batched reference laboratory samples, urgent individual specimens, or both, because that decision changes tolerance for hands-on time and result latency.
PATH user evaluations of decentralized molecular diagnostics found that functionally similar cartridge-based systems varied in whether a mobile application guided workflows and displayed results, and in specimen compatibility beyond nasal or throat swabs [5]. Those operational differences were observable even among products with comparable intended use. The HHS bacterial diagnostics brief reaches the same caution: no single diagnostic technology is superior across all US healthcare settings, and sampling methodology, detection technique and turnaround time differ by product [7]. Comparison therefore requires anchoring products to a named service situation before scoring speed or menu breadth.
Throughput, sample types and menu coverage as independent axes
Throughput cannot be reduced to a headline number. The CDC assessment placed Thermo Fisher QuantStudio 5 Dx, Bio-Rad CFX Opus and Roche LightCycler PRO in a group for broad public health applications, while reserving QuantStudio 7 Pro, QIAGEN QIAcuity dPCR and Hologic Panther for settings where throughput or scale exceeds the first group [1]. The separation reflects intended deployment, not a universal hierarchy. PFSCM similarly emphasizes that instrument utilization should be tested across disease programs, because consolidating HIV VL and EID volumes can determine whether a platform remains economically viable [3].
Sample type compatibility creates a second decision risk. The overview of automated molecular diagnostics lists sputum, nasal swab, plasma, whole blood, dried blood spot and plasma separation card as inputs, with quantitative viral load and qualitative EID as distinct output classes [3]. A procurement brief that specifies only respiratory swabs will miss whether the same platform can accept blood matrices for future programs. For syndromic panels, BD states that its molecular instruments are designed to route each sample based on urgency, volume and testing requirements, placing high-volume routine workloads on BD COR and specialized lower-volume testing on BD MAX [2]. Such vendor-described routing should be verified against the facility's own staffing and sample mix rather than accepted as a neutral feature.
A suggested scoring approach for a district hospital referral laboratory
As a suggestion rather than a tested model, a district hospital evaluating HIV viral load and EID could first define required specimen matrices as plasma, whole blood and dried blood spot, then assign a weighted score across five PFSCM-derived categories: polyvalent menu fit, throughput under existing staff, procurement modality and volume commitment, service response coverage, and compatibility with legacy data workflows [3]. Vendor claims for each category should be recorded separately from observed evidence. PATH-style usability tasks with simulated samples could be added for finalist platforms when decentralized use is contemplated [5].
Finally, the candidate list should be checked against the CDC distinction between platforms suited to broad applications and those reserved for throughput-demanding scenarios, because that separation signals when a specific instrument class is appropriate [1]. Score differences should be used to request targeted service and consumable terms rather than to declare a single winner across all sites. Where published comparisons lack local service or cost data, procurement teams should state that the outcome is conditional and verify through structured vendor demonstrations.
Procurement modality shapes total cost and service accountability
PFSCM contrasts three example modalities: direct purchase, hybrid arrangements and all-inclusive procurement. Direct purchase involves acquiring all components individually and carries greater logistics risk for the recipient; all-inclusive pricing bundles test cost components and platform placement, but typically requires minimum test volumes and supplier performance indicators; hybrid sits between them, possibly including service and maintenance or equipment leasing without annual volume commitment [3]. These are financial structures, not instrument properties, so two platforms with identical list pricing can diverge substantially once service response and consumable supply terms are compared.
Volume commitments explain why modality should precede shortlisting. An inclusive agreement may place an instrument at no additional cost, but minimum test volumes are required, making utilization forecasts a contractual variable [3]. The same guidance asks whether legacy direct purchase platforms could be transitioned to inclusive agreements and whether testing can be integrated across disease programs to meet thresholds [3]. Distribution and service access are the limiting counterpart. A review of sample-to-result platforms in low- and middle-income countries found service availability in only a limited number of countries was among the most significant implementation challenges, with one manufacturer lacking remote service from the instrument and requiring manual case submission after error report download [4].
Software, interoperability and evidence limitations
Software evaluation should differentiate run control from enterprise data management. In the Thermo Fisher qPCR brochure, Diomni Enterprise Software is described as connecting to multiple instruments, enabling automated quality control, result interpretation, configurable reporting, lab information system integration and concurrent users with role-based access; the QuantStudio 7 Pro Dx documentation also states the system passed penetration testing fulfilling FDA cybersecurity guidance [6]. These are vendor claims about documented capabilities. Procurement teams should verify which elements are included with the instrument and which require separate software or interface configuration.
Published comparisons reveal where evidence is thin. The sample-to-result review scored platforms on diagnostic coverage, cost, and distribution and service, with reported averages of 3.77 points for GeneXpert, 3.20 for BD Max, 3.01 for BioFire and 2.93 for Cobas Liat, but identified a literature base in which operational characteristics and clinical utility were rarely assessed [4]. The HHS research brief reviewed studies from 2018 through 2024 and found limited data on diagnostic uptake in individual hospitals, noting that high installation cost may push facilities toward outsourcing and that per-test costs vary after installation [7]. As a result, comparison models that rely solely on published scores may overstate certainty about local performance.
Usability, training burden and decentralized operation
PATH conducted structured usability assessments with seven to nine participants per technology and heuristic reviews by experienced analysts, then evaluated a sixth product with end users at LACEN in Brazil and FAMED-UEM in Mozambique [5]. Observations linked unclear instructions to steps with high risk of failure, indicating that training burden should be measured by observed workflow errors, not assumed from cartridge simplicity. Portability, power requirements and sample preparation complexity were cited as especially important for community-based and primary care environments [5].
This evidence matters for comparison because specifications rarely capture operator friction. PATH notes that low-throughput point-of-care technologies cannot easily replace high-volume platforms for surveillance unless batching is feasible [5]. A buyer comparing a decentralized cartridge system with a centralized batch analyzer must therefore quantify result volume per shift, staffing skill and supply chain maturity alongside quoted availability. The HHS brief similarly warns that transportation challenges can arise when facilities outsource testing because local installation is too expensive [7].
Sources & references
- DELIBERATIVE AND PREDECISIONAL SENSITIVE BUT UNCLASSIFIED, NOT FOR FURTHER DISTRIBUTION · aphl.org
- Molecular Diagnostic Solutions - BD · www.bd.com
- PFSCM-Procurement-of-Automated-Molecular-Diagnostics ... · pfscm.org
- Full article: Sample-to-result molecular diagnostic platforms and their suitability for infectious disease testing in low- and middle-income countries · www.tandfonline.com
- Decentralizing molecular diagnostics: Four insights from user evaluations | PATH · www.path.org
- Discover the power of molecular diagnostics · www.thermofisher.com
- Availability and Access of Bacterial Infection Diagnostics in the United States — Research Brief December 23, 2024 · aspe.hhs.gov